Acute Lymphoblastic Leukaemia Recurrent Recruiting Phase 1 Trials for Sorafenib (DB00398)

Also known as: Acute, recurrent Lymphoblastic Leukaemia / Acute, recurrent Lymphoblastic Leukemia / Recurrent Acute lymphoblastic leukemia / Acute, relapsed Lymphoblastic Leukemia / Relapsed Acute Lymphoblastic Leukemia / Acute lymphoblastic leukemia recurrent / Relapsed ALL / Acute lymphocytic leukemia recurrent / Acute lymphocytic leukaemia recurrent

IndicationStatusPhase
DBCOND0083559 (Acute Lymphoblastic Leukaemia Recurrent)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03878524Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTreatment
NCT03132454Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory LeukemiaTreatment